Surrozen, Inc.

NASDAQ•SRZN

執行長: Mr. Craig C. Parker M.B.A.

板塊: Healthcare

行業: Biotechnology

上市日期: 2021-01-11

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

聯絡資訊

171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, 94080, United States

650-489-9000

www.surrozen.com

市值

$245.06M

本益比 (TTM)

-2.8

17.8

股息率

52周最高

$29.60

52周最低

$5.90

52周範圍

96%

排名43Top 50.7%

3.8

F-Score

改良版 Piotroski 分析

基於 6 年期基本面

疲弱 • 3.8 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2020-2025

財務儀表板

Q3 2025 數據

營業收入

$983.00K-90.17%

近4季度走勢

每股收益

-$8.36+1800.00%

近4季度走勢

自由現金流

-$9.06M+34.24%

近4季度走勢

2025 Q3 財報亮點

核心亮點

Significant 2025 PIPE Funding Nine months financing provided 71.3M USD, primarily from the March 2025 PIPE proceeds, bolstering capital resources.

Related Party Revenue Surge Research service revenue reached 2.9M USD for nine months, driven by the TCGFB collaboration agreement executed in 2024.

Strong Cash Position Maintained Cash and equivalents totaled 81.3M USD as of September 30, 2025, supporting operations for at least 12 months.

SZN-8141 IND Filing Expected The company anticipates filing the Investigational New Drug application for SZN-8141 during 2026 to commence clinical studies.

關注風險

Net Loss Widened Significantly Nine month net loss increased 66% to 58.9M USD in 2025, driven by higher R&D expenses and non-cash charges.

Operating Expenses Increased Total operating expenses rose 20% to 32.4M USD for nine months, primarily due to 29% growth in R&D spending.

TCGFB Collaboration Terminated Research Collaboration with TCGFB terminated effective November 2025, eliminating future related party revenue streams.

Future Capital Requirements High Expect continued losses and substantial additional capital needed to advance pipeline through clinical development and regulatory submissions.

未來展望

Advance Key Ophthalmology Candidates Strategy focuses on advancing SZN-8141 and SZN-8143 through IND filing and into Phase 1 clinical studies in 2026.

Discontinued SZN-043 Development Development of SZN-043 halted in Q1 2025 due to insufficient early signal of clinical benefit for severe alcohol associated hepatitis.

2025 ATM Program Inactive The 50.0M USD At-the-Market program established in August 2025 has not yet resulted in any common stock sales as of period end.

Maintain Intellectual Property Rights Continued focus on securing and defending patent rights for Wnt platform and product candidates against potential third-party challenges.

同行對比

營業收入 (TTM)

AGEN

$106.83M

-33.4%

MGX

$30.91M

-43.9%

ZNTL

$26.87M

-33.8%

毛利率 (最新季度)

SRZN

100.0%

+0.0pp

IRD

99.6%

-0.4pp

TCRX

71.8%

-30.5pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
ARMP	$399.02M	-8.5	70.3%	198.5%
GLSI	$341.79M	-17.3	-1042.8%	0.0%
IRD	$328.96M	-4.9	-774.2%	3.0%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

14.5%

穩定增長

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

25%

現金流需要關注

深度研究

下次財報:2026年3月19日

每股收益:-$1.29

營業收入:$661.00K

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料